본문으로 건너뛰기
← 뒤로

Hashimoto Thyroiditis and Progression of Papillary Thyroid Cancer: 10-Year Retrospective Cohort Study.

JMIR cancer 2026 Vol.12() p. e80535

Li X, Yao X, Shan R, Mei F, Song S, Sun B, Yuan C, Liu Z

📝 환자 설명용 한 줄

[BACKGROUND] In recent years, the global incidence of thyroid cancer has been increasing.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 90
  • p-value P=.003
  • p-value P=.01
  • 95% CI 0.61-1.99

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Li X, Yao X, et al. (2026). Hashimoto Thyroiditis and Progression of Papillary Thyroid Cancer: 10-Year Retrospective Cohort Study.. JMIR cancer, 12, e80535. https://doi.org/10.2196/80535
MLA Li X, et al.. "Hashimoto Thyroiditis and Progression of Papillary Thyroid Cancer: 10-Year Retrospective Cohort Study.." JMIR cancer, vol. 12, 2026, pp. e80535.
PMID 41494178
DOI 10.2196/80535

Abstract

[BACKGROUND] In recent years, the global incidence of thyroid cancer has been increasing.

[OBJECTIVE] This study aimed to examine the association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) progression under active surveillance (AS).

[METHODS] Our retrospective study was conducted at Peking University Third Hospital and included 203 patients with PTC who underwent AS for ≥6 months before surgery. Patients were first categorized into 2 groups: the HT group (n=90) and the non-HT group (n=113). Cox proportional hazards models were then used to evaluate the association between HT and PTC progression during AS, adjusting for age, sex, baseline tumor size, BMI, pregnancy status, number of tumor foci, and thyroid-stimulating hormone level. Subgroup analyses stratified by the 6 covariates mentioned above were also applied to explore the potential effect modification.

[RESULTS] No significant difference was observed between the HT and non-HT groups in PTC progression-free survival (hazard ratio [HR] 1.11, 95% CI 0.61-1.99; P=.74), tumor enlargement-free survival (HR 1.02, 95% CI 0.56-1.86; P=.95), or lymph node metastasis-free survival (HR 1.76, 95% CI 0.31-10.12; P=.52). Subgroup analyses revealed a potential interaction between HT and BMI. Among patients who were overweight or obese (BMI >24 kg/m²), HT was significantly associated with an increased risk of disease progression (HR 6.32, 95% CI 1.84-21.69; P=.003), while among patients with BMI ≤24 kg/m2, no association between HT and progression risk was observed (P=.01).

[CONCLUSIONS] We found no evidence of association between HT and PTC progression during AS. However, the relationship between HT and PTC progression may be modified by overweight or obesity status.

MeSH Terms

Humans; Hashimoto Disease; Female; Retrospective Studies; Male; Thyroid Cancer, Papillary; Middle Aged; Thyroid Neoplasms; Disease Progression; Adult; Proportional Hazards Models; Follow-Up Studies

같은 제1저자의 인용 많은 논문 (5)